A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT07940803

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07940803
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07940803. Randomized; triple masking; primary purpose treatment. Start 2026-11-13 (anticipated); primary completion 2028-03-25 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes
Condition
Overweight
Condition
Obesity
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
NNC0662-3168 (Test product-A)
Intervention (Drug)
Placebo matched to NNC0662-3168 (Test product-A)
Intervention (Drug)
Active Comparator (Product-B)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07940803
Content hash
0232a0611499b20fef9c99b88844a8ea818414df411a686926f8d031488d4544